Category Archives: Pharmaceutical Trademarks
Merck to Acquire IOMet Pharma
Merck has agreed to pay up to $400 million to acquire IOmet Pharma, a Scottish company that specializes in the development of small molecule-based cancer treatments. IOmet will operate as a division of Merck. The acquisition will include IOmet’s pre-clinical pipeline … Continue reading
Bayer Loses CTM Opposition
On 29 October 2015, OHIM’s Opposition Division of the Office dismissed Bayer’s opposition against registration of the mark SALOSPIR & Design (No. 012351458). Bayer opposed Uni-Pharma SA’s application for the mark SALOSPIR & Design for pharmaceutical preparations in Class 5 based on three … Continue reading
Ipsen & Telesta Reach Deal
Ipsen and Telesta Therapeutics Inc. announced yesterday that they have entered into an exclusive licensing agreement for Ipsen to develop and commercialize MCNA1 for the treatment of high risk non-muscle invasive bladder cancer (NMIBC) in all countries of the world, … Continue reading
Darren Geliebter
Mathew Lombard
THE PRINCIPAL REGISTER 